Is the expression pattern of BD ProExC the same as Ki-67? A comparative analysis in cervical biopsies

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 3, 2010, Pages 262-267

  Walts, Ann E ^a   Bose, Shikha ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cervical intraepithelial neoplasia (CIN); Ki 67; ProExC

Indexed keywords

BD PROEXC; BIOLOGICAL MARKER; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL METAPLASIA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOPSY; CELL CYCLE PROTEINS; CELL PROLIFERATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; EPITOPES; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NUCLEAR PROTEINS; PAPILLOMAVIRUS INFECTIONS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 77951748497     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181c1f99f     Document Type: Article

References (34)

1. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferationassociated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123: 513-522.
2. Indinnemo M, Cicchini C, Stazi A, et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res. 2000;19:471-475.
3. Walts AE, Bose S. P16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol. 2009;40:957-964. Epub ahead of print March 5, 2009.
4. Badr RE, Walts AE, Chung F, et al. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol. 2008;32:899-906.
5. Pinto AP, Schlecht NF, Woo TY, et al. Biomarker (ProEx C, p16 (INK4a), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol. 2008;21:1067-1074.
6. Beccati MD, Buriani C, Pedriali M, et al. Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquid-based cervical squamous cell cytology. Cancer. 2008;114:196-203.
7. Halloush RA, Akpolat I, Jim Zhai Q, et al. Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer. 2008;114:474-480.
8. Akpolat I, Smith DA, Ramzy I, et al. The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material. Cancer. 2004;102:142-149.
9. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res. 2003;63:1927-1935.
10. Malinowski DP. Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection. Expert Rev Mol Diagn. 2007;7:117-131.
11. Shi J, Liu H, Wilkerson M, et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol. 2007;38:1335-1344.
12. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV 16- and HPV 18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331:269-291.
13. Madine MA, Swietlik M, Pelizon C, et al. The roles of the MCM, ORC and Cdc6 proteins in determining the replication competence of chromatin in quiescent cells. J Struct Biol. 2000;129:198-210.
14. Musahl C, Holthoff HP, Lesch R, et al. Stability of the replicative MCM3 protein in proliferating and differentiating human cells. Exp Cell Res. 1998;241:260-264.
15. Stoeber K, Tlsty TD, Happerfield L, et al. DNA replication licensing and human cell proliferation. J Cell Sci. 2001;114:2027-2041.
16. Chatrath P, Scott IS, Morris LS, et al. Aberrant expression of minichromosome maintenance protein-2 and Ki67 in laryngeal squamous epithelial lesions. Br J Cancer. 2003;89:1048-1054.
17. Davidson EJ, Morris LS, Scott IS, et al. Minichromosome maintenance (MCM) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer. 2003;88:257-262.
18. Chan KY, Walts AE, Bose S. ProExC is a marker for HPVassociated anal lesions. Mod Pathol. 2007;20(suppl 2):109A.
19. Scott IS, Morris LS, Bird K, et al. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol. 2003;201:187-197.
20. Going JJ, Keith WN, Neilson L, et al. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut. 2002;50:373-377.
21. Karimi S, Mohammadi F, Khodadad K, et al. High expression of minichromosome maintenance protein 6 in classic Hodgkin's lymphoma points to a cell cycle arrest in G1 phase. Arch Iran Med. 2008;11:532-538.
22. Nishihara K, Shomori K, Fujioka S, et al. Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance. Int J Oncol. 2008;33:245-251.
23. Hunt DP, Freeman A, Morris LS, et al. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance- 2 protein. Br J Neurosurg. 2002;16:10-15.
24. Schrader C, Janssen D, Klapper W, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005;93:939-945.
25. Huang HY, Huang WW, Lin CN, et al. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol. 2006;13:1633-1644.
26. Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005;11:2510-2517.
27. Szelachowska J, Dziegiel P, Jelen-Kreszewska J, et al. MCM-2 protein expression predicts prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma. Anticancer Res. 2006;26:2473-2478.
28. Kruger S, Thorns C, Stocker W, et al. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder. Eur Urol. 2003;43:138-145.
29. Burger M, Denzinger S, Hartmann A, et al. MCM2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK 20, Ki67, and histological grade. Br J Cancer. 2007; 96:1711-1715. Epub May15, 2007.
30. Mattila R, Alanen K, Syrjanen S. Immunohistochemical study on topoisomerase IIalpha, Ki-67, and cytokeratin-19 in oral lichen planus lesions. Arch Dermatol Res. 2007;298:381-388. Epub October 28, 2006.
31. Manaios L, Tsiambas E, AlevizakiM, et al. Comparative toposiomerase IIa and Ki67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis. J BUON. 2008;13: 537-541.
32. Nielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol. 2008;47:725-734.
33. Kosari F, Munz JM, Savci-Heijink CD, et al. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008; 14:1734-1743.
34. Helleman J, Jansen MP, Span PN, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2006;118: 1963-1971.